Omicron variant

NICD research suggests BA.2 is nothing to worry about – Photo: Adobe Stock

COVID-19 latest: SA reports 10 008 new reported cases, 190 deaths

The NICD has said on Sunday a further 190 COVID-19 related deaths have been reported, bringing total fatalities to 74 813 to date.

Omicron variant

NICD research suggests BA.2 is nothing to worry about – Photo: Adobe Stock

South Africa recorded 10 008 new cases of COVID-19 in the last 24 hours, the National Institute for Communicable Diseases (NICD) has said on Sunday. 

This brings the total number of laboratory-confirmed cases to 2 533 466. 

This increase of 10 008 new COVID-19 cases represents a 22.8 % positivity rate. 

A further 190 COVID-19 related deaths have been reported, bringing total fatalities to 74 813 to date on Sunday.

“The cumulative number of recoveries is 2,297 974.” 

A total of 75 hospital admissions has been reported in the past 24 hours.

The Western Cape province is still in the lead with the majority of new cases: 2 913 (29%), followed by KwaZulu-Natal with 2 270 new cases (23%) and Gauteng with 1 690 new cases (17%) provinces. 

For more detailed information, visit the GIS Dashboard.

15 257 317 tests have been conducted in both public and private sectors.

There’s some good news on the vaccine front: The Sisonke Implementation Study has found that the Johnson & Johnson COVID-19 vaccine is effective against the Delta variant, which accounted for South Africa’s third wave and spread quite rapidly.

The results of the study were presented by its co-principal lead Professor Glenda Gray, on Friday, 6 August 2021. Gray said the findings indicate that there is great protection against COVID-19 hospitalisation and death.

“Protection is good against both the Beta and the Delta variant. There was 67% protection against hospitalisation with the Beta variant and 71% protection against hospitalisation with the Delta variant,” she said.

Gray said their data shows that there is better efficacy against Delta than there is against the Beta.

More than 477 000 healthcare workers were administered the J&J vaccine at the start of the trial back in February.

ALSO READ: Vaccine latest: J&J EFFECTIVE against Delta variant, study finds